The efficacy and safety of 30 mg fexofenadine HCI bid in pediatric patients with allergic rhinitis

Asian Pacific Journal of Allergy and Immunology

Volumn 23, Issue 4, 2005, Pages 169-174

  Ngamphaiboon, Jarungchit ^a   Direkwattanachai, C ^b   Visitsunthorn, N ^c   Vangveeravong, M ^d   Tiensuwan, M ^e  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^e Mahidol University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; FEXOFENADINE;

ALLERGIC RHINITIS; ARTICLE; ASIAN; CARDIOTOXICITY; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE DISCHARGE; EYE IRRITATION; FEMALE; HAY FEVER; HEADACHE; HUMAN; KAPPA STATISTICS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE DRUG DOSE; NASAL PRURITUS; NOSE CONGESTION; OCULAR PRURITUS; OPEN STUDY; PALATE DISEASE; PATIENT SATISFACTION; PERENNIAL RHINITIS; PRICK TEST; RHINORRHEA; SCORING SYSTEM; SNEEZING; STATISTICAL SIGNIFICANCE; THAILAND; THROAT IRRITATION; TREATMENT OUTCOME;

ANTI-ALLERGIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MULTICENTER STUDIES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TERFENADINE; TREATMENT OUTCOME;

EID: 33645320577     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Nathan RA, Meltzer EO, Selner JC et al. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99: s8O8-14.
2. Vuurman ER, Van Veggel LM, Uiterwijk MM et al. Seasonal allergic rhinitis and antihistamine effects on children' learning. Ann Allergy 1993; 71: 121-6.
3. Simons FER. Histamine and HI-antihistamines in allergic disease. Marcel Dekker Inc, New York, 2002.
4. Handley DA, Magnetti A, Higgins AJ. Therapeutic advantages of third generation antihistamine. Expert Opin Invest Drug 1998; 7: 1045-54.
5. Howarth PH, Stem MA, Roi L et al. Double-blind, placebo controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927-33.
6. Bronsky EA. Falliers CJ, Kaiser HB et al. Effectiveness and safety of fexofenadine, a new nonsedating HI-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc 1998; 19: 135-41.
7. Bernstein DI, Schoenwetter WF, Nathan RA et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 443-8.
8. Casale TB, Andrade C, Qu R. Safety and efficacy of once daily fexofenadine HCI in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc 1999; 20: 193-8.
9. Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine HCl 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000; 30: 891-9.
10. Mason J, Reynold R, Rao N. The systemic safety of fexofenadine HC Clin Exp Allergy 1999; 29 (Suppl): 163-73.
11. Simons FE, Bergman JN, Watson WT et al. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol 1996; 88:1062-4.
12. Graft DF, Bernstein DI, Goldsobel A et al. Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001; 87: 22-6.
13. Simon FER. Learning impairment in allergic rhinitis. Allergy Asthma Proc 1996; 17: 185-9.
14. Fuiman P. Treatment strategies designed to minimize medical complications of allergic rhinitis. Am J Rhinol 1997; 11: 95-102.
15. Greisner WA 3rd, Settipane RJ, Settipane GA. Co-existence of asthma and allergic rhinitis; a 23 year follow-up study of college students. Allergy Asthma Proc 1998; 19: 185-8.
16. Hindmarch I. Shamsi Z. Antihistamines: model to access the sedative properties, assessment of sedation, safety and other side effects. Clin Exp Allergy 1999; 29 (Suppl): 133-42.
17. Howarth PH, Wilson S, Lau L et al. The nasal mast cell and rhinitis. Clin Exp Allergy 1991; 21: 3-8.
18. Kemp JP, Buckley CE, Gershwin ME et al. Multicenter, double blind, placebo-controlled trial of terfenadine in seasonal allergic rhinitis and conjunctivitis. Ann Allergy 1985; 54: 502-9.
19. Clissold SP, Sorkin EM, Goa KL. Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1989; 37: 42-57.
20. Wahn U, Meltzer EO, Finn AF et al. Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. J. Allergy Clin Immunol 2003; 111: 763-9.
21. de Paulis A, Dente V, Onorati AM et al. Fexofenadine inhibits the release of mediators and IL-4 from human FcεRI+ cells. Allergy 1999; 54 (Suppl): 144 (Abstract p278).
22. Pratt CM, Mason J, Russell T et al. Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999; 83: 1451-4.